Abstract Details

Title Effects of Solriamfetol on Neuropsychological Outcomes in Patients With Obstructive Sleep Apnea in the Real-world SURWEY Study

Topic Sleep

Presentation(s) P6 - Poster Session 6 (5:00 PM-6:00 PM)

Poster/Presentation
Number 14-005

Objective To evaluate the effect of solriamfetol treatment on neuropsychological outcomes in patients with excessive daytime sleepiness (EDS) associated with obstructive sleep apnea (OSA) in the real-world SURWEY study.

Background Patients with EDS associated with OSA often exhibit cognitive deficits. Solriamfetol (Sunosi®) is a dopamine-norepinephrine reuptake inhibitor and TAAR1/5HT1A agonist approved to treat EDS associated with narcolepsy or OSA. Solriamfetol demonstrated improvements in cognitive performance in participants with EDS and cognitive impairment associated with OSA in the Phase 4 randomized SHARP study.

Design/Methods SURWEY was a retrospective, observational study using data from physicians prescribing solriamfetol for EDS associated with narcolepsy and OSA. Neuropsychological assessments were performed in a subgroup of patients with OSA prior to and 3 months after solriamfetol initiation. Tests included: Test of Attentional Performance (TAP) subtest alertness, the Regensburger Word Fluency Test, the Wechsler Memory Scale subtest visual reproduction, Wechsler Adult Intelligence Scale (WAIS-IV) subtest coding, and British Columbia Cognitive Complaints Inventory (BC-CCI).

Results Before solriamfetol initiation, participants (N=46) showed impaired alertness on the TAP (mean±SD 268.2±21.8 ms with warning signal, 270.2±21.9 ms without), impaired cognitive function on the BC-CCI (8.6±2.2), and reduced psychomotor and visual processing speed on the WAIS-IV coding subtest (7.1±1.5); no impairments in word fluency or memory were observed. Following solriamfetol treatment, TAP scores improved by a mean of 11.4% (237.7±21.4 ms with warning; 239.5±21.3 ms without, p<0.01 for both). BC-CCI scores improved by a mean of 40.8% (5.1±3.1, p<0.01). WAIS-IV coding scores improved by 30.6% (9.3±1.8, p<0.01). Epworth Sleepiness Scale scores improved by 4.7±2.7 (p<0.01); change in EDS was not associated with cognitive improvement (|r|=0.16, p=0.3).

Conclusions In this observational study, solriamfetol reduced OSA-associated cognitive impairment, independently of improvements in EDS.

Authors/Disclosures
Yaroslav Winter PRESENTER	Prof. Winter has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Angelini Pharma. Prof. Winter has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bioprojet. Prof. Winter has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai. Prof. Winter has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Idorsia Pharmaceuticals. Prof. Winter has received personal compensation in the range of $500-$4,999 for serving as a Consultant for JAZZ Pharmaceuticals. Prof. Winter has received personal compensation in the range of $500-$4,999 for serving as a Consultant for LivaNova. Prof. Winter has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB Pharma. Prof. Winter has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Presisis.
Graham M. Eglit, PhD	Dr. Eglit has received personal compensation for serving as an employee of Axsome Therapeutics Inc. Dr. Eglit has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Developmental Neuropsychology: A Life-Span Developmental Journal. Dr. Eglit has stock in Axsome Therapeutics.
Samantha Floam, DMD (Axsome Therapeutics)	Dr. Floam has received personal compensation for serving as an employee of Axsome Therapeutics.
Ulf Kallweit	Ulf Kallweit has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Takeda. Ulf Kallweit has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bioprojet. Ulf Kallweit has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Takeda. Ulf Kallweit has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bioprojet. Ulf Kallweit has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bioprojet. Ulf Kallweit has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Pharmanovia. Ulf Kallweit has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier.

��ɫ��

��ɫ��